2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
复制标题
DOI：
10.1161/cir.0000000000001063
复制
发表时间：
2022-05-03
期刊：
影响因子：
37.8
通讯作者：
Yancy, Clyde W.
中科院分区：
文献类型：
--
作者：
Heidenreich, Paul A.;Bozkurt, Biykem;Yancy, Clyde W.
目的：“2022年AHA/ACC/HFSA心力衰竭管理指南”取代了“2013年ACCF/AHA心力衰竭管理指南”和“2017年ACC/AHA/HFSA重点更新2013年ACCF/AHA心力衰竭管理指南”。“2022年指南旨在为临床医生提供以患者为中心的建议，以预防，诊断和管理心力衰竭患者。研究方法：从2020年5月至2020年12月进行了一次全面的文献检索，包括在MEDLINE（PubMed）、EMBASE、科克伦协作网、美国医疗保健研究和质量管理局以及其他相关数据库中以英文发表的针对人类受试者进行的研究、综述和其他证据。还考虑了截至2021年9月发表的其他相关临床试验和研究。该指南与截至2021年12月发布的其他美国心脏协会/美国心脏病学会指南保持一致。结构：心力衰竭仍然是全球发病率和死亡率的主要原因。2022年心力衰竭指南根据当代证据为这些患者的治疗提供了建议。这些建议提出了一种以证据为基础的方法来管理心力衰竭患者，旨在提高护理质量并符合患者的利益。早期心力衰竭指南中的许多建议已经更新了新的证据，并在发表的数据支持下创建了新的建议。为某些治疗提供了价值报表，并附有高质量的已发表经济分析。
Aim: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. Methods: A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. Structure: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.